148 related articles for article (PubMed ID: 38444654)
1. Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.
Isobe K; Nakamura Y; Sakamoto S; Tomii K; Takimoto T; Miyazaki Y; Matsumoto M; Sugino K; Ichikado K; Moriguchi S; Yamaguchi K; Baba T; Ozasa H; Igata F; Anabuki K; Homma S; Date H; Suda T; Kishi K
ERJ Open Res; 2024 Mar; 10(2):. PubMed ID: 38444654
[TBL] [Abstract][Full Text] [Related]
2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
3. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
4. Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.
Sun X; Song Z; Jiang H; Ma Y; Chen M
Clin Imaging; 2022 Jun; 86():31-37. PubMed ID: 35325631
[TBL] [Abstract][Full Text] [Related]
5. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
9. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
10. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
Ng KYY; Tan SH; Tan JJE; Tay DSH; Lee AWX; Ang AJS; Wong LWJ; Choo SP; Tai DW; Lee JJX
Liver Cancer; 2022 Jan; 11(1):9-21. PubMed ID: 35222504
[TBL] [Abstract][Full Text] [Related]
11. Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.
Barrón F; Sánchez R; Arroyo-Hernández M; Blanco C; Zatarain-Barrón ZL; Catalán R; Ramos-Ramírez M; Cardona AF; Flores-Estrada D; Arrieta O
Front Oncol; 2020; 10():570233. PubMed ID: 33117699
[TBL] [Abstract][Full Text] [Related]
12. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
13. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Shi Y; Fang J; Zhou C; Liu A; Wang Y; Meng Q; Ding C; Ai B; Gu Y; Yao Y; Sun H; Guo H; Zhang C; Song X; Li J; Xu B; Han Z; Song M; Tang T; Chen P; Lu H; Shui Y; Lou G; Zhang D; Liu J; Liu X; Liu X; Gao X; Zhou Q; Chen M; Zhao J; Zhong W; Xu Y; Wang M
Thorac Cancer; 2022 Feb; 13(3):412-422. PubMed ID: 34935288
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
[TBL] [Abstract][Full Text] [Related]
17. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
18. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
Inomata M; Matsumoto M; Hayashi K; Seto Z; Hirai T; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2023 Jul; 43(7):3241-3246. PubMed ID: 37351972
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
